EMAIL THIS PAGE TO A FRIEND

Biochimica et biophysica acta

A novel proteolysis-resistant cyclic helix B peptide ameliorates kidney ischemia reperfusion injury.


PMID 25220479

Abstract

Helix B surface peptide (HBSP), derived from erythropoietin, displays powerful tissue protection during kidney ischemia reperfusion (IR) injury without erythropoietic side effects. We employed cyclization strategy for the first time, and synthesized thioether-cyclized helix B peptide (CHBP) to improve metabolic stability and renoprotective effect. LC-MS/MS analysis was adopted to examine the stability of CHBP in vitro and in vivo. The renoprotective effect of CHBP in terms of renal function, apoptosis, inflammation, extracellular matrix deposition, and histological injury was also detected in vivo and in vitro. Antibody array and western blot were performed to analyze the signal pathway of involvement by CHBP in the IR model and renal tubular epithelial cells. In this study, thioether-cyclized peptide was significantly stable in vivo and in vitro. One dose of 8nmol/kg CHBP administered intraperitoneally at the onset of reperfusion improved renal protection compared with three doses of 8nmol/kg linear HBSP in a 48h murine IR model. In a one-week model, the one dose CHBP-treated group exhibited remarkably improved renal function over the IR group, and attenuated kidney injury, including reduced inflammation and apoptosis. Interestingly, we found that the phosphorylation of autophagy protein mTORC1 was dramatically reduced upon CHBP treatment. We also demonstrated that CHBP induced autophagy via inhibition of mTORC1 and activation of mTORC2, leading to renoprotective effects on IR. Our results indicate that the novel metabolically stable CHBP is a promising therapeutic medicine for kidney IR injury treatment.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV36578
Anti-ANXA3 (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV36579
Anti-ANXA3 (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB1405458
Anti-ANXA3 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA013398
Anti-ANXA3 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA013431
Anti-ANXA3 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1305638 ANTI-LC3 (APG8A) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
L8793
Anti-LC3A antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB1408113
Anti-MAP1LC3A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA007649
Anti-MAP1LC3A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101425
Anti-MAP1LC3A antibody produced in rabbit, affinity isolated antibody
SAB4300571
Anti-MAP1LC3A antibody produced in rabbit, affinity isolated antibody
SAB1411514
Anti-MAP1LC3A antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB3501064
Anti-MAP1LC3A antibody produced in rabbit, affinity isolated antibody
WH0000306M12
Monoclonal Anti-ANXA3 antibody produced in mouse, clone 4F1, purified immunoglobulin, buffered aqueous solution
SAB1403553
Monoclonal Anti-ANXA3 antibody produced in mouse, clone 1E2, purified immunoglobulin, buffered aqueous solution
SAB4100143
Monoclonal Anti-ANXA3 antibody produced in mouse, clone ANXA3-A107, culture supernatant
WH0084557M7
Monoclonal Anti-MAP1LC3A antibody produced in mouse, clone 1D5, purified immunoglobulin, buffered aqueous solution